Yahoo Finance

ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation

ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd ...
PharmiWeb

ReiThera to Unveil ReiCell-AAV Platform for High-Efficiency Gene Therapy AAV Production, Adding to MVA and GRAd Vector Capabilities

First look at ReiCell-AAV next week at Advanced Therapies London, Booth 94 With three cutting-edge platforms for gene therapy and genetic vaccine production, ReiThera remains unique among CDMOs Rome, ...
Pharmabiz

ReiThera, Ragon Institute of Mass General, MIT, and Harvard, & IAVI collaborate to advance highly networked T cell HIV vaccine candidate towards phase I clinical evaluation

ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd ...